Clinical Publications

Clinical Publications

Progenity conducts and publishes ongoing research, to encourage open sharing of ideas and information that can lead to better patient care.

A prospective verification study demonstrates that the Preecludia™ test has high sensitivity and high negative predictive value.

Findings suggest CHEK2 variants may be associated with uterine and pancreatic cancers, as well as other cancer types.

Ingestible capsule that analyzes intestinal fluid in real time is as accurate, faster, and less invasive compared to the current clinical standard.

Current diagnostic methods for small intestinal bacterial overgrowth (SIBO) can be invasive, costly, or unreliable. A novel ingestible capsule shows promise as a preferred tool for SIBO diagnosis.

The effects of lysosomal storage diseases (LSDs) can be devastating. However, some LSDs have available treatments that can prevent or delay symptoms and prolong survival when administered early in life. Learn more about carrier frequency for these diseases and the impact of carrier testing.

Hereditary cancer risk assessment is standard of care in obstetrics and gynecology (ob/gyn) practice. Chatbots can help assess who is at risk.

Attention to readability and health literacy is critical for informed consent forms. But most consent forms marketed by commercial laboratories aren't given the attention they deserve.

Cell-free DNA screening is specially designed to tell you about fetal chromosome abnormalities. But did you know it will sometimes tell you something clinically significant about mom?

At inception, the ability to detect aneuploidy in twin pregnancies using cell-free DNA (cfDNA) was rightfully doubted. But there is now increasing data supporting the use of cfDNA screening for twin pregnancies.

Historical data indicated 1 in 12 women were at risk for hereditary cancer. New data suggest we were significantly underestimating this risk. Find out more about the new data here.